Global Fibromyalgia Treatment Market

Fibromyalgia Treatment Market Size, Share, Growth Analysis, By Drug class(Antidepressants, Antiepileptic, Muscle relaxants, Others), By Distribution Channels(Hospital pharmacies, Retail pharmacies, Online pharmacies), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35A2821 | Region: Global | Published Date: July, 2024
Pages: 219 | Tables: 64 | Figures: 67

Fibromyalgia Treatment Market Competitive Landscape

The competitive environment of the global Fibromyalgia Treatment market  is dynamic and characterized by the presence of a mix of well-established brands, emerging players, and niche producers. Innovation is a key competitive factor. Leading brands invest in research and development to introduce new flavors, packaging formats, and health-focused variations to cater to changing consumer preferences. They often set the trends in the industry. 

Top Player’s Company Profiles

  • Pfizer, Inc.
  • Eli Lilly and Company
  • AbbVie, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Johnson & Johnson Services, Inc
  • Sanofi
  • GlaxoSmithKline plc.
  • Bayer AG
  • TONIX Pharmaceuticals Holdings Corp
  • Virios Therapeutics, Inc.
  • Aptinyx Inc.
  • FSD Pharma

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Fibromyalgia Treatment Market size was valued at USD 1.3 billion in 2022 and is poised to grow from USD 1.39 billion in 2023 to USD 2.39 billion by 2031, growing at a CAGR of 7.00% in the forecast period (2024-2031). 

The competitive environment of the global Fibromyalgia Treatment market  is dynamic and characterized by the presence of a mix of well-established brands, emerging players, and niche producers. Innovation is a key competitive factor. Leading brands invest in research and development to introduce new flavors, packaging formats, and health-focused variations to cater to changing consumer preferences. They often set the trends in the industry.  'Pfizer, Inc.', 'Eli Lilly and Company', 'AbbVie, Inc.', 'Teva Pharmaceutical Industries Ltd.', 'Johnson & Johnson Services, Inc', 'Sanofi', 'GlaxoSmithKline plc.', 'Bayer AG', 'TONIX Pharmaceuticals Holdings Corp', 'Virios Therapeutics, Inc.', 'Aptinyx Inc.', 'FSD Pharma'

Prominent players in the fibromyalgia treatment market are proactively involved in the introduction of innovative therapies, aiming to establish or fortify their market presence. The imminent launches and approvals of novel treatments dedicated to fibromyalgia are anticipated to contribute significantly to market growth in the forecast period. One illustrative example is the case of Galcanezumab, developed by Eli Lilly and Company, which is currently undergoing a phase 4 clinical trial as of January 2021. Originally approved for the treatment of migraine and cluster headache, Galcanezumab is poised to complete its pivotal clinical end-stage by December 2021, specifically for the treatment of fibromyalgia. This strategic expansion of indications for existing drugs exemplifies the commitment of major pharmaceutical companies to address the complex and evolving needs of fibromyalgia patients.

North America exhibited substantial revenue generation in the fibromyalgia treatment market, amounting to USD 1,253.5 million, and is anticipated to maintain predominant market growth throughout the projected time frame. This growth can be attributed to a higher rate of diagnosis and the prevalence of fibromyalgia in the region, coupled with the broader availability of advanced approved products for managing the disease.  

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Fibromyalgia Treatment Market

Report ID: SQMIG35A2821

$5,300
BUY NOW GET FREE SAMPLE